control group:Icotinib

2 trials

Sponsors

Longhua Hospital, Shanghai University of Traditional Chinese Medicine

Conditions

Advanced adenocarcinoma lung cancer

Early Phase 1

A randomized, controlled, double-blind study of Fuzheng Jiedu granules in combination with icotinib in the first-line treatment of EGFR-sensitive mutated advanced lung adenocarcinoma

Active, not recruitingITMCTR2000003632

Longhua Hospital, Shanghai University of Traditional Chinese MedicineAdvanced adenocarcinoma lung cancer

Start: 2020-10-01Updated: 2023-02-20

A randomized, controlled, double-blind study of Fuzheng Jiedu granules in combination with icotinib in the first-line treatment of EGFR-sensitive mutated advanced lung adenocarcinoma

Active, not recruitingChiCTR2000036256

Longhua Hospital, Shanghai University of Traditional Chinese MedicineAdvanced adenocarcinoma lung cancer

Start: 2020-10-01Updated: 2020-09-07